65,437 trials
Skin Laxity
Primary: Number of Treatment Samples With Different Levels of Elastin When Compared to Baseline Samples From the Same Patient — 0 biopsy samples
Sensorineural Hearing Loss
Primary: Change in Speech Reception Threshold (SRT) — 5.3 dB
Central Nervous System Indication · Pediatric Patients · Body Indication
Primary: Elimination Half-life — 1.29; 1.48; 1.77 hours
Cerebral Palsy
Primary: Oxygen Consumption (ml/kg/Min) — 14.82; 16.75; 28.77 ml/kg/min
Cataract
Primary: Proportion of Eyes With Surgeon Satisfaction Rating Score of 4 or 5 — 0.991; 0.991; 0.991; 1.00 Proportion of Eyes
Asthma
Primary: Forced Expiratory Volume in One Second (FEV1) % Predicted Trough Change From Baseline (Mean Observed in the 2 Weeks Prior to Treatment) After Six Weeks of Treatment…
Cheek Augmentation
Primary: Assess Efficacy of Study Treatment Using Medicis Midface Volume Score (MMVS) — -1.4; -0.1; -1.3 score on a scale
Asthma
Primary: Forced Expiratory Volume in One Second (FEV1) % Predicted Trough Change From Baseline (Mean Observed in the 2 Weeks Prior to Treatment) After Six Weeks of Treatment…
Glaucoma · Primary Open Angle Glaucoma · Secondary Glaucoma
Primary: Intraocular Pressure After Surgery — 13.1; 16.2 mmHg
Primary Biliary Cholangitis
Primary: Percentage of Participants With Response to Composite Endpoint of ALP <1.67 × Upper Limit of Normal [ULN], ≥15% Reduction in ALP, and Total Bilirubin ≤ ULN) at Month 3…
Carcinoma, Small Cell
Primary: Number of Participants With Objective Tumor Response — 0; 0 Participants
Back Pain Without Radiation · Low Back Pain
Primary: Change From Baseline to Day 5 in Functional Impairment — 11.9; 9.4; 10.9 score on a scale
Non-alcoholic Fatty Liver Disease (NAFLD) · Non-alcoholic Steatohepatitis (NASH)
Primary: Safety (Including Hepatic Safety) and Tolerability of MEDI0382 Compared With Placebo: Number of Participants With TEAE and SAE — 20; 22; 9; 0 Participants
Diabetic Foot Ulcer
Primary: Number of Participants With a Clinical Outcome of "Clinical Cure" — 14; 7 Participants
Brain and Central Nervous System Tumors
Primary: Phase 1b Escalation Phase: Number of Participants With Dose-Limiting Toxicities (DLTs) as Assessed by CTCAE — 0; 0; 2; 1 participants